본문

  1. Home
1000 Results:PP:ELSEVIER INC 0.312 sec.
RSS 
다국어입력
 상세검색
 신착검색
선택출력 선택엑셀내보내기
51
Early clinical data to support the clinical relevance of RANKL inhibition
Early clinical data to support the clinical relevance of RANKL inhibition
Adolfo Diez- Rerez, | Elsevier Inc | 2011 ,
52
Effect of RANKL inhibition on bone mass,structure, and strength in animal models
Effect of RANKL inhibition on bone mass,structure, and strength in animal models
Serege Ferrari, | Elsevier Inc | 2011 ,
53
The RANK/RANKL/OPG system as a primary regulatory pathway for bone resorption
The RANK/RANKL/OPG system as a primary regulatory pathway for bone resorption
Hofbauer L.C., | Elsevier Inc | 2011 ,
54
Unmet medical need in the management of postmenopausal osteoporosis
Unmet medical need in the management of postmenopausal osteoporosis
Roux C., | Elsevier Inc | 2011 ,
55
Where do we stand on vitamin D?
Where do we stand on vitamin D?
Bischoff-Ferrari, H. A., | Elsevier Inc | 2007 ,
56
HSA: Beyond BMD with DXA
HSA: Beyond BMD with DXA
Lou Bonnick, S., | Elsevier Inc | 2007 ,
57
Is Cortical Bone Hip? What determines Cortical Bone Properties?
Is Cortical Bone Hip? What determines Cortical Bone Properties?
Epstein, S., | Elsevier Inc | 2007 ,
58
Ibandronate: An IV injection for the treatment for postmenopausal osteoporosis
Ibandronate: An IV injection for the treatment for postmenopausal osteoporosis
Rizzoli, R., | Elsevier Inc | 2007 ,
59
Bisphosphonate action on bone structure and strength: Preclinical and clinical evidence for ibandronate
Bisphosphonate action on bone structure and strength: Preclinical and clinical evidence for ibandronate
Müller, R., | Elsevier Inc | 2007 ,
60
Bisphosphonate antifracture efficacy
Bisphosphonate antifracture efficacy
Adami, S., | Elsevier Inc | 2007 ,
처음이전12345678910이후마지막